MassChallenge Startups Create Impact

2,458

Startups Accelerated

$6.2B

Funding Raised

$3B

Revenue Generated

157,000+

Jobs Created

Our startups

Be inspired. Search our startups.

Clear  
Cogentis Therapeutics

Cogentis Therapeutics is developing a drug to treat a family of neurodegenerative disorders, including Alzheimer's Disease, and our initial target condition, Frontotemporal Degeneration, also known as Frontotemporal Dementia (FTD).

Our drug can cross into the brain and prevent the process which leads to neural decay, dementia, and cell death. Due to advances in medical technology, we can target a previously inaccessible pathway and disrupt FTD before it begins.
Cogentis Therapeutics is working on a novel and potential disease-modifying peptide therapeutic for Alzheimer's and FTD.

Connect with Cogentis Therapeutics

Cogentis Therapeutics

2020

2015 Silver Boston

2020 Finalist Boston

Sub industry

Therapeutics (Pharma / Biotech)

Mission

MassChallenge strengthens the global innovation ecosystem by accelerating high-potential startups across all industries, from anywhere in the world.